Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· March 13, 2026

The Buckle (BKE) Q4 2025 Earnings Call Transcript

View original at nasdaq.com
The Buckle (BKE) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. DATE Friday, March 13, 2026 at 10 a.m. ET CALL PARTICIPANTS Chief Financial Officer — Thomas B…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Current plans for fiscal 2026 include opening 12-14 new stores and completing 12-14 full remodel projects

    60% confidence

  • Kids business remains a key area of opportunity for growth and earning new guests from a young age

    60% confidence

  • The wide leg denim trend has provided another fashion item to work with traditional fits, expanding selection

    60% confidence

  • Inventory build was strategic to ensure the company could support heightened demand and service guests in style, fits, sizes, and inseams

    60% confidence

  • The Buckle Black label exceeded the growth of the overall denim category and had exceptional performance

    60% confidence

  • The company has been very successful with premium and Tanger outlet stores and is taking an opportunistic approach to store openings

    60% confidence

  • Q4 2025 marked the fifth consecutive quarter of double-digit growth for the women's business

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com